BCM
MYGN icon

Boreal Capital Management’s Myriad Genetics MYGN Stock Holding History

Boreal Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206 Hold
36
– – ﹤0.01% 493
2026
Q1 		$162 Hold
36
– – ﹤0.01% 487
2025
Q4 		$221 Hold
36
– – ﹤0.01% 501
2025
Q3 		$260 Hold
36
– – ﹤0.01% 510
2025
Q2 		$191 Buy
+36
New +$213 ﹤0.01% 475

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boreal Capital Management's MYGN Position: Q2 2026 in Review

Boreal Capital Management held its Myriad Genetics (MYGN) position steady in Q2 2026 at 36 shares worth $206. The position accounts for ﹤0.01% of the portfolio, ranked #493.

Boreal Capital Management first reported a position in MYGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $260 in Q3 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Boreal Capital Management held 36 shares of Myriad Genetics worth $206 as of Q2 2026.
  • Boreal Capital Management left its Myriad Genetics share count unchanged in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Boreal Capital Management's portfolio in Q2 2026, its #493 holding.
  • Boreal Capital Management first reported a position in Myriad Genetics in Q2 2025 and has held it in 5 quarters since.
  • Boreal Capital Management's Myriad Genetics position peaked at $260 in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Boreal Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.